Literature DB >> 17223542

Who gets screened, and where: a comparison of organised and opportunistic mammography screening in Geneva, Switzerland.

Eric Chamot1, Agathe I Charvet, Thomas V Perneger.   

Abstract

It is unclear whether introducing organised mammography screening programmes in a population where opportunistic screening is prevalent results in the two types of screening mainly competing against each other or attracting different groups of women. To compare women who participate in organised screening and those who prefer opportunistic screening, we conducted a prospective study of 932 women followed for 8 months after an invitation to participate in the first round of an organised screening programme in Geneva, Switzerland. All women were aged 50-69 years and were due for a mammogram according to local guideline. Of the 932 participants, 11.6% had an organised and 39.4% an opportunistic mammogram during follow-up. Women who were in the stage of contemplation, had favourable attitude toward mammography screening, and perceived their risk of breast cancer to be high were more likely to have a mammogram (either organised or opportunistic). Compared to women who had an opportunistic mammogram, women with an organised mammogram were less positive about screening, less likely to be in maintenance at baseline (adjusted odds ratio (OR), 3.0; 95% confidence interval (CI), 1.7-5.5), to have a history of benign breast disease (OR, 2.4; 95% CI, 1.2-5.1) and to perceive their financial situation as comfortable (OR, 1.7; 95% CI, 1.1-2.8). Although screening uptake was low, the programme appeared to attract women in lower socio-economic strata who did not usually undergo mammography screening.

Entities:  

Mesh:

Year:  2007        PMID: 17223542     DOI: 10.1016/j.ejca.2006.10.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme.

Authors:  Ondrej Majek; Jan Danes; Miroslava Skovajsova; Helena Bartonkova; Lucie Buresova; Daniel Klimes; Petr Brabec; Pavel Kozeny; Ladislav Dusek
Journal:  BMC Public Health       Date:  2011-05-10       Impact factor: 3.295

2.  Sex differences associated with hepatitis B virus surface antigen seropositivity unwareness in hepatitis B virus surface antigen-positive adults: 2007-2012 Korea National Health and Nutrition Examination Survey.

Authors:  Suk-Yong Jang; Sung-In Jang; Hong-Chul Bae; Jaeyong Shin; Eun-Cheol Park
Journal:  J Prev Med Public Health       Date:  2015-03-16

3.  Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study.

Authors:  Caroline Bähler; Beat Brüngger; Agne Ulyte; Matthias Schwenkglenks; Viktor von Wyl; Holger Dressel; Oliver Gruebner; Wenjia Wei; Eva Blozik
Journal:  BMC Public Health       Date:  2021-01-05       Impact factor: 3.295

4.  Cancer screening in a middle-aged general population: factors associated with practices and attitudes.

Authors:  Stéphane Cullati; Agathe I Charvet-Bérard; Thomas V Perneger
Journal:  BMC Public Health       Date:  2009-04-29       Impact factor: 3.295

5.  Small-area spatio-temporal analyses of participation rates in the mammography screening program in the city of Dortmund (NW Germany).

Authors:  Dorothea Lemke; Shoma Berkemeyer; Volkmar Mattauch; Oliver Heidinger; Edzer Pebesma; Hans-Werner Hense
Journal:  BMC Public Health       Date:  2015-11-28       Impact factor: 3.295

6.  Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies.

Authors:  Christian Herrmann; Penelope Vounatsou; Beat Thürlimann; Nicole Probst-Hensch; Christian Rothermundt; Silvia Ess
Journal:  BMJ Open       Date:  2018-03-14       Impact factor: 2.692

7.  A national cross-sectional study of adherence to timely mammography use in Malta.

Authors:  Danika Marmarà; Vincent Marmarà; Gill Hubbard
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.